{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:52:03Z","timestamp":1787615523306,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,6,17]],"date-time":"2012-06-17T00:00:00Z","timestamp":1339891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00277-012-1506-2","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T23:14:25Z","timestamp":1342912465000},"page":"1773-1778","source":"Crossref","is-referenced-by-count":23,"title":["Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan"],"prefix":"10.1007","volume":"91","author":[{"given":"Shang-Yin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,17]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncr.22850","volume":"110","author":"SY Huang","year":"2007","unstructured":"Huang SY, Yao M, Tang JL et al (2007) Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25\u00a0years and higher prevalence of extramedullary myeloma in patients younger than 55\u00a0years. Cancer 110:896\u2013905","journal-title":"Cancer"},{"key":"1506_CR2","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, Sezer O, Kyle R et al (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716\u20131730","journal-title":"Leukemia"},{"key":"1506_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","volume":"84","author":"SK Kumar","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84:1095\u20131110","journal-title":"Mayo Clin Proc"},{"key":"1506_CR4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825\u2013831","journal-title":"Lancet"},{"key":"1506_CR5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet 370:1209\u20131218","journal-title":"Lancet"},{"key":"1506_CR6","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol 27:3664\u20133670","journal-title":"J Clin Oncol"},{"key":"1506_CR7","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","volume":"21","author":"MA Diamopoulos","year":"2003","unstructured":"Diamopoulos MA, Anagnostopoulos A, Weber D (2003) Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21:4444\u20134454","journal-title":"J Clin Oncol"},{"key":"1506_CR8","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","volume":"27","author":"A Falanga","year":"2009","unstructured":"Falanga A, Marchetti M (2009) Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27:4848\u20134857","journal-title":"J Clin Oncol"},{"key":"1506_CR9","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","volume":"111","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Facon T, Sonneveld P et al (2008) Thalidomide for treatment of multiple myeloma: 10\u00a0years later. Blood 111:3968\u20133977","journal-title":"Blood"},{"key":"1506_CR10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","volume":"154","author":"JA Snowden","year":"2011","unstructured":"Snowden JA, Ahmedzai SH, Ashcroft J et al (2011) Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154:76\u2013103","journal-title":"Br J Haematol"},{"key":"1506_CR11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614\u20131615","journal-title":"Blood"},{"key":"1506_CR12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414\u2013423","journal-title":"Leukemia"},{"issue":"Suppl 4","key":"1506_CR13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70136-7","volume":"123","author":"RH White","year":"2009","unstructured":"White RH, Keenan CR (2009) Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 123(Suppl 4):S11\u2013S17","journal-title":"Thromb Res"},{"key":"1506_CR14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1253\/circj.71.761","volume":"71","author":"S Suzuki","year":"2007","unstructured":"Suzuki S, Yamashita T, Kato T et al (2007) Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 71:761\u2013765","journal-title":"Circ J"},{"key":"1506_CR15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","volume":"344","author":"FK Chan","year":"2001","unstructured":"Chan FK, Chung SC, Suen BY et al (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967\u2013973","journal-title":"N Engl J Med"},{"key":"1506_CR16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-009-0807-6","volume":"89","author":"Y Koh","year":"2010","unstructured":"Koh Y, Bang SM, Lee JH et al (2010) Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 89:201\u2013206","journal-title":"Ann Hematol"},{"key":"1506_CR17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Cavo M, Bringhen S et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29:986\u2013993","journal-title":"J Clin Oncol"},{"key":"1506_CR18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/JCO.1986.4.1.80","volume":"4","author":"R Bataille","year":"1986","unstructured":"Bataille R, Durie BG, Grenier J, Sany J (1986) Prognostic factor sand staging in multiple myeloma: a reappraisal. J Clin Ocnol 4:80\u201387","journal-title":"J Clin Ocnol"},{"key":"1506_CR19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/07357900701208808","volume":"25","author":"TJ Chiou","year":"2007","unstructured":"Chiou TJ, Wang TH, Chao TY et al (2007) Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest 25:140\u2013147","journal-title":"Cancer Invest"},{"key":"1506_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00277-003-0700-7","volume":"82","author":"SY Huang","year":"2003","unstructured":"Huang SY, Tang JL, Yao M et al (2003) Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol 82:558\u2013564","journal-title":"Ann Hematol"},{"key":"1506_CR21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","volume":"97","author":"M Kropff","year":"2012","unstructured":"Kropff M, Giongco Baylon H, Hillengass J et al (2012) Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica 97:784\u2013791","journal-title":"Haematologica"},{"key":"1506_CR22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991\u2013995","journal-title":"Ann Oncol"},{"key":"1506_CR23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"A Anagnostopoulos","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768\u2013771","journal-title":"Br J Haematol"},{"issue":"6 Suppl","key":"1506_CR24","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"WH Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S\u2013453S","journal-title":"Chest"},{"key":"1506_CR25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1001\/archinte.162.19.2197","volume":"162","author":"SM Weisman","year":"2002","unstructured":"Weisman SM, Graham DY (2002) Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162:2197\u20132202","journal-title":"Arch Intern Med"},{"key":"1506_CR26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1523-5378.2007.00496.x","volume":"12","author":"DB Lin","year":"2007","unstructured":"Lin DB, Lin JB, Chen CY et al (2007) Seroprevalence of Helicobacter pylori infection among schoolchildren and teachers in Taiwan. Helicobacter 12:258\u2013264","journal-title":"Helicobacter"},{"key":"1506_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","volume":"116","author":"EJ Libourel","year":"2010","unstructured":"Libourel EJ, Sonneveld P, van der Holt B et al (2010) High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 116:22\u201326","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1506-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1506-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T08:42:49Z","timestamp":1561970569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,17]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1506-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,17]]}}}